# Reimbursement as the real gate to commercial value
FDA approval feels like the finish line. It is not. A device can clear the FDA, sit on a shelf, and never generate a dollar of revenue. The reason is almost always the same: no one figured out who pays, how much, and under what billing code.
Consider the pattern seen across digital therapeutics and novel diagnostics in recent years. Companies celebrated FDA clearance, issued a press release, and then hit a wall. Physicians wanted to use the product. Patients wanted access. But hospitals could not bill for it, insurers would not cover it, and sales flatlined. The regulatory gate opened. The commercial gate stayed shut.
This lesson explains why reimbursement, not regulatory clearance, determines whether revenue materializes, and how to read that risk as a finance professional.
There are two separate approvals a medtech or biotech product must clear, and they answer different questions.
Regulatory clearance (FDA) answers: *Is this product safe and effective?* The FDA does not care whether anyone will pay for it.
Reimbursement answers: *Will a payer pay for it, and through what mechanism?* This is decided by a different set of actors entirely, and it is where commercial value is actually created or destroyed.
A useful mental model: FDA approval gives you the *right to sell*. Reimbursement gives you the *ability to get paid*. Only the second one shows up on the income statement.
Getting paid in the US health system requires three things to line up. Miss any one and revenue stalls.
A code is the standardized identifier a provider uses to bill for a service or product. The most important set for physician services is CPT (Current Procedural Terminology), maintained by the American Medical Association. There are also HCPCS codes (for products, supplies, and drugs) and ICD-10 codes (for diagnoses).
Without a code, there is often no clean way to submit a claim. A provider using a novel device may have to bill under a Category III CPT code (temporary, for emerging services) or an unlisted code, both of which get scrutinized, delayed, or denied more often. A permanent Category I CPT code signals the procedure is established, and it takes years of clinical evidence and AMA review to obtain.
You can browse how the AMA describes this process at the AMA CPT overview.
Coverage is a payer's decision that it will pay for a given service for a given patient population. Medicare issues these as National Coverage Determinations (NCDs) or Local Coverage Determinations (LCDs). Private insurers publish their own medical policies.
Coverage is not automatic once a code exists. A payer can acknowledge the code and still say "not medically necessary" or "experimental and investigational," which means no payment. This is the most common quiet killer of a promising device.
Even with a code and coverage, the payment amount must make the product economically viable for the provider. If a hospital gets reimbursed less than the cost of using the device, it will not adopt it, no matter how good the technology is.
Medicare sets rates through fee schedules and inpatient/outpatient payment systems (for example, the DRG system for hospital stays, which bundles payment for an entire episode). If a new device gets swept into an existing bundle at no extra payment, the hospital effectively eats the cost. Manufacturers sometimes pursue special add-on payments (like Medicare's New Technology Add-on Payment, or NTAP) to bridge this gap temporarily.
Picture a device cleared by the FDA that performs a novel, non-invasive diagnostic scan. The clinical case is strong. Here is how the money problem unfolds.
The fix is slow and expensive: generate clinical and economic evidence, apply to the AMA for a permanent code, and simultaneously lobby payers for coverage. This can take three to five years or more after FDA clearance. For a venture-backed company burning cash, that gap is often fatal.
The lesson: a code is not a formality. It is the plumbing that lets revenue flow.
For anyone valuing a biotech or medtech asset, reimbursement risk must be an explicit input, not an afterthought buried in "commercial assumptions."
Build a reimbursement timeline separate from the regulatory timeline. FDA approval in Year 3 does not mean revenue in Year 3. Model the code and coverage lag explicitly. Revenue ramp often begins one to four years *after* approval.
Stress-test the payment rate. Ask: what does the provider net after using this product? If the answer is negative or thin, adoption assumptions are fantasy. This is the "does the economics work for the buyer" test, and buyers here are hospitals and physicians, not patients.
Distinguish existing-code from new-code paths. A product that fits neatly into an established, well-paid code carries far less commercial risk than one requiring a brand-new code. In diligence, "we plan to obtain a CPT code" is a red flag, not a plan.
Watch the evidence requirement. Payers increasingly demand real-world outcomes and health-economic data, not just the safety-and-efficacy data the FDA accepted. Budget for post-approval studies as a cost of getting paid.
A simple framing for a diligence checklist:
| Question | Good sign | Red flag |
|---|---|---|
| Is there an existing code? | Category I CPT already covers it | Needs a new code |
| Is there coverage? | Positive NCD/LCD or major payer policy | "Experimental" designation |
| Does the rate cover provider cost? | Clear positive margin for the buyer | Bundled with no add-on |
| Evidence for payers? | RWE and economic data in hand | Only FDA pivotal trial |
For a primer on how Medicare coverage decisions actually get made, the CMS Medicare Coverage Database is a free, authoritative resource.
Knowledge check
1. A digital therapeutic receives FDA clearance but generates no revenue in its first year despite strong physician and patient interest. Based on the lesson's reasoning, what is the most likely explanation?
2. The lesson describes FDA approval as the 'right to sell' and reimbursement as the 'ability to get paid.' What is the key implication of this distinction for a finance professional?
3. Regulatory clearance and reimbursement answer fundamentally different questions. Which pairing correctly matches each gate to the question it answers?
4. Select ALL correct answers about the three pillars of reimbursement and the role of coding in the US health system.
Select all the correct answers.
5. Select ALL correct answers that reflect why a finance professional should treat reimbursement as a distinct risk from regulatory risk.
Select all the correct answers.
The best-run medtech and biotech companies treat reimbursement as a core strategic function that starts *before* the pivotal trial, not after FDA approval.
Design trials that satisfy payers, not just the FDA. If a payer will want to see reduced hospitalizations or lower total cost of care, build those endpoints into the study early. Retrofitting evidence later costs years.
Engage payers pre-launch. Companies increasingly hold early conversations with major insurers to understand what evidence would unlock coverage. This is called establishing the value propositionvalue propositionA clear statement of the benefits your product delivers, the problems it solves and why customers should choose you over alternatives.View full definition → in payer terms: not "it works" but "it saves you money or improves outcomes you are accountable for."
Sequence the code strategy. Some companies launch under a temporary code while assembling the evidence for a permanent one, accepting slow early revenue as the price of market presence.
The financial implication is blunt: two companies with identical FDA-cleared technology can have wildly different valuations based purely on reimbursement position. The one with an established code, positive coverage, and a workable rate is a commercial asset. The one still hunting for a code is a science project with regulatory validation.